3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Gemcitabine
25
Cisplatin
19
pembrolizumab
11
avelumab
10
Nivolumab
7
Mitomycin
6
Carboplatin
6
apaziquone
5
Paclitaxel
5
Vinblastine
4
Methotrexate
4
Doxorubicin
4
Docetaxel
4
BCG Vaccine
4
vofatamab
3
durvalumab
3
atezolizumab
3
Sunitinib
3
Standard of Care
3
Sorafenib
3
Radiotherapy, Intensity-Modulated
3
Radiotherapy
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Lapatinib
3
Cystectomy
3
B701 protein, Human herpesvirus 6
3
valrubicin
2
rucaparib
2
enfortumab vedotin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Urinary Bladder Neoplasms
×
trilaciclib
×
Clear all
NCT04887831
2025-09-08
PRESERVE3
G1 Therapeutics, Inc.
Phase 2
Terminated
92 enrolled
24 charts